Literature DB >> 17218576

A single dose of dexamethasone to prevent postbronchoscopy fever in children: a randomized placebo-controlled trial.

Elie Picard1, Shmuel Goldberg, Dov Virgilis, Shepard Schwartz, David Raveh, Eitan Kerem.   

Abstract

STUDY
OBJECTIVE: To assess the effectiveness of one dose of dexamethasone (0.5 mg/kg; maximum, 10 mg) to prevent fever after bronchoscopy with BAL.
DESIGN: Randomized, placebo-controlled study. PATIENTS: Immunocompetent nonfebrile children undergoing fiberoptic bronchoscopy with BAL. MEASUREMENTS AND
RESULTS: Sixty-nine children were included in the study. Thirty-eight children received saline solution, and 31 children received dexamethasone. The two groups were similar regarding the number of children < 2 years old, the percentage of abnormal bronchoscopic findings, the number of positive BAL culture findings, and the index of lipid-laden macrophages. Twenty-six children (68%) in the saline solution group (SG) had fever, compared to 3 children (9.6%) in the dexamethasone group (DG) [p < 0.001]. Fever after the procedure appeared later (12.3 +/- 5.5 h) in the DG compared to 5.4 +/- 2.7 h in the SG.
CONCLUSIONS: One dose of dexamethasone administered prior to performing bronchoscopy with BAL may prevent fever subsequent to the procedure. Further studies are necessary in order to determine the optimal dosing regimen for dexamethasone when used for this purpose.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17218576     DOI: 10.1378/chest.06-0337

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  2 in total

1.  Construction of a Risk Prediction Model for Fever After Painless Bronchoscopy.

Authors:  Zhang-Hong Lv; Niu Yuan
Journal:  Med Sci Monit       Date:  2020-07-08

2.  The potential role of postbronchoscopic fever on the postoperative outcomes in patients with non-small cell lung cancer.

Authors:  Haoshuai Zhu; Jianyong Zou; Chunhua Su; Yiyan Lei; Bo Zeng; Zhenguang Chen; Honghe Luo
Journal:  J Thorac Dis       Date:  2018-02       Impact factor: 2.895

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.